Contents
On this page
- Definition of regulatory writing
- Regulatory documents and their governing guidelines
- The current name of the ICH
- The clinical study report
- Relocation of the Investigator’s Brochure within ICH E6
- The protocol and the ICH M11 template
- Safety reporting
- Medical device documentation as a separate system
- Working practices
Academy · Regulatory writing · Understanding regulatory writing
Understanding Regulatory Writing: Governing Guidelines from Research Data to Submission
The structure of a regulatory document is not a matter of judgement. Nearly every such document has a named guideline behind it, and the first question to ask of any of them is which guideline applies.
Regulatory writing is the preparation of the documents that a medicines or device regulator requires, in the structure specified by that regulator or by the relevant harmonised guideline. Its distinguishing feature is that the structure is not a matter of judgement: nearly every document has a named guideline behind it, and the first question about any of them is which guideline applies.
Definition of regulatory writing
It differs from other scientific writing in one structural way. A journal article is written to a reporting guideline and a house style, and the author has latitude within both. A regulatory document is written to a specified structure, and departures from it are queries waiting to happen.
So the useful thing a guide can give you is not advice about clarity — though clarity matters — but the map from document to governing guideline. That is this page.
Regulatory documents and their governing guidelines
Table 1. Regulatory documents and the guideline that specifies each
| Document | Governing guideline | Notes |
|---|---|---|
| Clinical study report (CSR) | ICH E3 | Structure and content of the report of one clinical study. Sixteen sections. |
| Investigator's Brochure (IB) | ICH E6(R3), Appendix A | Was Section 7 in E6(R2). Compiles the clinical and non-clinical data relevant to the investigational product. |
| Clinical study protocol | ICH E6(R3), Appendix B; ICH M11 for the template | Was Section 6 in E6(R2); an SOP citing “E6 Section 6” therefore now refers to the wrong location. The M11 structured template was adopted at Step 4 in November 2025 and comes into effect in June 2026. |
| Expedited safety reports | ICH E2A | Definitions and standards for expedited reporting. |
| Individual case safety reports | ICH E2B | Data elements and electronic transmission. |
| Common Technical Document (CTD) | ICH M4, currently M4(R4) | The five-module organisation of a marketing authorisation application. |
| CTD content by discipline | ICH M4Q, M4S, M4E | Quality, safety and efficacy respectively. M4E governs the clinical module. |
| Electronic submission | ICH M8 | The eCTD. A submission format, not a content architecture. |
| Clinical evaluation report (CER) | MDR Article 61 and Annex XIV Part A | An EU medical device document, not an ICH one. Different sector, different authority. |
Three things are worth drawing out of that table, because each is a mistake we see in draft documents.
M4E is the one most often left unnamed. It governs the clinical overview and clinical summary in CTD Module 2 and the organisation of Module 5 — which is to say, the clinical argument of a marketing application8. A documentation plan that names M4Q and M4S but not M4E has left the largest module without a guideline.
The eCTD is a different guideline from the CTD. M4 is the content architecture7; M8 is the electronic submission specification9. Our page on CTD structure covers that distinction in full.
Device documents are not ICH documents. A clinical evaluation report belongs to EU device law, not to the ICH framework, and the two systems are not interchangeable. That is the last section of this page.
The current name of the ICH
The International Council for Harmonisation. It was the International Conference on Harmonisation until 2015, when it was reorganised and established as a non-profit legal entity under Swiss law — its own history records the body as “The International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation (ICH)”1, and that “it was reformed and established as a non-profit legal entity under Swiss Law on 23 October 2015.”1
There are two reasons for using the name correctly. The outdated name immediately dates a document for a regulatory reader, and the use of “ICH” without expansion prevents a reader unfamiliar with the abbreviation from looking it up.
For which revision of a guideline is current, a regulator’s own list is more reliable than the guideline documents themselves, which do not always state it cleanly10.
The clinical study report
ICH E3, Step 4 on 29 November 19952. Its objective is “to facilitate the compilation of a single core clinical study report acceptable to all regulatory authorities of the ICH regions”2 — one report, accepted everywhere, instead of one per region.
It specifies sixteen numbered sections:
Table 2. The sixteen sections of an ICH E3 clinical study report
| Section | |
|---|---|
| 1 | Title page |
| 2 | Synopsis |
| 3 | Table of contents |
| 4 | List of abbreviations and definitions |
| 5 | Ethics |
| 6 | Investigators and study administrative structure |
| 7 | Introduction |
| 8 | Study objectives |
| 9 | Investigational plan |
| 10 | Study patients |
| 11 | Efficacy evaluation |
| 12 | Safety evaluation |
| 13 | Discussion and overall conclusions |
| 14 | Tables, figures and graphs referred to but not in the text |
| 15 | Reference list |
| 16 | Appendices |
Two practical notes. Section 2, the synopsis, is what most readers read, and it is written last from the finished report rather than first. And sections 14 and 16 — the tables and figures not placed in the text, and the appendices — are where the bulk of a large report sits; planning them late is the usual cause of a timeline overrun.
E3 has had no revision of the guideline itself. Whether a separate questions-and-answers addendum is current could not be confirmed from a regulator-hosted source, so this page does not assert that one exists.
Relocation of the Investigator’s Brochure within ICH E6
Implications for document templates
The Investigator's Brochure is specified in ICH E6. Its location moved between revisions: it is Appendix A in E6(R3) and was Section 7 in E6(R2). A document or template that cites “ICH E6 Section 7” without naming the revision refers to the wrong location in the current guideline.
The current revision of Good Clinical Practice is E6(R3), adopted at Step 4 on 6 January 20253. It follows E6(R2), which was an integrated addendum to E6(R1) and was adopted on 9 November 20164.
One point of care in how that is described: the R3 text does not itself contain a statement that it replaces R2. So the defensible wording is that R3 is the current revision, rather than a quoted supersession.
The practical consequence of the move is organisational rather than scientific. Standard operating procedures, document templates and training material that cross-reference “E6 Section 7” now point to the wrong place, and the fix is a cross-reference audit rather than a rewrite.
The protocol and the ICH M11 template
The protocol is governed by E6, and since late 2025 there is also a harmonised template: ICH M11, the Clinical electronic Structured Harmonised Protocol, adopted at Step 4 on 19 November 2025 and coming into effect on 11 June 20266, with a companion technical specification.
Worth knowing about now rather than later, for two reasons. It is recent enough that most regulatory writing guidance in circulation does not mention it. And it is a template and specification, not a replacement for E6 — the GCP obligations are unchanged; what M11 standardises is the structure the protocol is written into.
Safety reporting
These are two guidelines with different functions, and they are commonly conflated.
ICH E2A covers the definitions and the standards for expedited reporting, effective since 1 June 19955. Its own statement of purpose: “This document aims to develop standard definitions and terminology for key aspects of clinical safety reporting.”5 This is the guideline that tells you what has to be reported and how quickly.
ICH E2B specifies the data elements and the electronic transmission of individual case safety reports — the content and format of the report itself rather than the trigger for making one.
E2B, currently at revision R3, specifies the data elements and electronic transmission of individual case safety reports. Its exact title and Step 4 date could not be confirmed from a regulator-hosted copy, so neither is given here. The appropriate division is E2A for definitions and expedited reporting and E2B for the content and transmission of individual case safety reports.
Medical device documentation as a separate system
A regulatory writer moving between medicines and devices needs to hold two frameworks apart. ICH guidelines govern medicines documentation across the ICH regions. EU device documentation is governed by Regulation (EU) 2017/745, which has applied since 26 May 202111.
So a clinical evaluation report is not an ICH document and has no ICH guideline; it is required by Article 61 and Annex XIV Part A of the MDR, and the working guidance comes from the Medical Device Coordination Group. Our page on the clinical evaluation report covers it, including the distinction from a clinical study report that this page's predecessor collapsed.
One distinction between the two systems should be noted: for a device clinical investigation, the Investigator's Brochure has its own MDCG guidance rather than following ICH E6. Check which system your study sits in before reaching for a template.
Working practices
Practical application
- Record the governing guideline and its current revision for every planned document before drafting. If no guideline can be named, the nature of the document has not yet been established.
- Check revisions against a regulator’s guideline list rather than against a previously obtained guideline PDF, which may not state what has superseded it.
- Audit templates and SOPs for cross-references to ICH E6 Section 7; the Investigator’s Brochure is Appendix A in E6(R3).
- Write “International Council for Harmonisation” in full on first use in anything dated after 2015.
- Name M4E explicitly in a CTD documentation plan, not only M4Q and M4S.
- Keep the submission format decision separate from the content architecture decision: M4 for what goes where, M8 for how it is transmitted.
- Plan the clinical study report’s appendices and out-of-text tables early. They are the bulk of the document and the usual cause of a late delivery.
- Where work spans medicines and devices, maintain two guideline maps. A device clinical evaluation report has no ICH guideline behind it.
Key points
Every regulatory document has a named guideline behind it, and identifying that guideline is the first step in writing one: ICH E3 for the clinical study report; E6(R3) for Good Clinical Practice and, in its Appendix A, the Investigator’s Brochure; M11 for the harmonised protocol template from June 2026; E2A and E2B for safety reporting; M4 for the CTD, with M4E governing the clinical module; and M8 for the eCTD. ICH has been the International Council for Harmonisation since 2015. A clinical evaluation report, by contrast, is not an ICH document; it falls under Regulation (EU) 2017/745.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. It was the International Conference on Harmonisation until 2015, when it was reorganised and established as a non-profit legal entity under Swiss law. On a current regulatory document, “Conference” is an error, and leaving the abbreviation unexpanded is also unhelpful.
ICH E3, Structure and Content of Clinical Study Reports, which reached Step 4 on 29 November 1995. It specifies sixteen numbered sections, from the title page and synopsis through to the appendices. Its own stated objective is a single core report acceptable to all the ICH regions, which is the point of writing to it rather than to one agency’s house style.
In ICH E6, but the location moved. It is Appendix A in E6(R3), the current revision adopted on 6 January 2025, and was Section 7 in E6(R2). A template or SOP that cites “ICH E6 Section 7” without naming the revision now refers to the wrong location.
ICH E6(R3), adopted at Step 4 on 6 January 2025. It follows E6(R2), which was itself an integrated addendum to E6(R1) and was adopted on 9 November 2016. Note that the R3 text does not contain a sentence declaring that it replaces R2, so the accurate description is that R3 is the current revision.
Yes, and it is more recent than much existing guidance acknowledges. ICH M11, the Clinical electronic Structured Harmonised Protocol, was adopted at Step 4 in November 2025 and comes into effect in June 2026, with a companion technical specification. It is a template and a specification, not a replacement for E6.
There are two, with different functions. ICH E2A covers the definitions and the standards for expedited reporting, and has been effective since June 1995. ICH E2B, currently at revision R3, specifies the data elements and the electronic transmission of individual case safety reports. E2A therefore governs what must be reported and when, and E2B the content and format of the report itself.
References
- International Council for Harmonisation. ICH 30th Anniversary Publication. ICH, 2021. read 15 October 2026. View on ICH, via ANVISAICH's own history. The source for the rename from Conference to Council, for the reconstitution as a Swiss non-profit on 23 October 2015, and for the distinction between the CTD as a structural guideline and the eCTD as the electronic exchange format.
- International Council for Harmonisation. E3: Structure and Content of Clinical Study Reports. Step 4 version, 29 November 1995. FDA Guidance for Industry, July 1996. read 15 October 2026. View on U.S. Food and Drug AdministrationThe guideline that specifies what a clinical study report contains. Sixteen numbered sections. No revision of the guideline itself exists; whether a separate questions-and-answers addendum is current could not be confirmed, so none is claimed here.
- International Council for Harmonisation. E6(R3): Guideline for Good Clinical Practice. Adopted 6 January 2025. read 15 October 2026. View on Pharmaceuticals and Medical Devices Agency, JapanThe current revision, adopted at Step 4 on 6 January 2025. The text itself does not contain a sentence declaring that it replaces R2, so this site describes it as the current revision rather than quoting a supersession statement.
- International Council for Harmonisation. Guideline for Good Clinical Practice E6(R2). EMA/CHMP/ICH/135/1995. Step 4 version, 9 November 2016. read 15 October 2026. View on European Medicines AgencyThe preceding revision, an integrated addendum to E6(R1). Cited because the Investigator's Brochure is Section 7 here and Appendix A in R3, so documents written against either revision point to a different place.
- International Council for Harmonisation. E2A: Clinical Safety Data Management — Definitions and Standards for Expedited Reporting. CPMP/ICH/377/95, effective 1 June 1995. read 15 October 2026. View on European Medicines AgencyThe guideline for expedited safety reporting and for the definitions underneath it. E2B covers the content and electronic transmission of individual case safety reports; its Step 4 date could not be confirmed and is not given.
- International Council for Harmonisation. M11: Clinical electronic Structured Harmonised Protocol (CeSHarP) — Template. Step 4 adopted 19 November 2025; coming into effect 11 June 2026. read 15 October 2026. View on European Medicines AgencyA harmonised protocol template with a companion technical specification. It is a template, not a replacement for E6, and it is newer than most regulatory writing guidance acknowledges.
- International Council for Harmonisation. ICH Harmonised Tripartite Guideline M4(R4): Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use. Step 4 version, 15 June 2016. read 15 October 2026. View on European Medicines AgencyThe guideline that defines the CTD's five-module organisation. The source for both Step 4 dates: the original CTD on 8 November 2000 and the R4 revision on 15 June 2016.
- International Council for Harmonisation. M4E(R2): The CTD — Efficacy. Step 4 version, 15 June 2016. FDA Guidance for Industry, July 2017. read 15 October 2026. View on U.S. Department of Health and Human ServicesThe guideline governing Module 5 and the clinical overview and summary. Its absence from a page describing the CTD leaves the clinical module without a guideline pointer.
- European Medicines Agency. ICH M8: Electronic Common Technical Document (eCTD) v4.0 — draft ICH implementation guide v2.0. EMA/CHMP/ICH/143002/2015 Rev. 1, Step 2. read 15 October 2026. View on European Medicines AgencyThe eCTD is ICH M8, a separate guideline from M4. Two specifications are live, v3.2.2 and v4.0. Conflating the CTD with the eCTD conflates a content architecture with an electronic submission specification.
- Medicines and Healthcare products Regulatory Agency. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. MHRA guidance. read 15 October 2026. View on GOV.UKA regulator's current list of ICH guidelines and revisions. Cited for which revision of each M4 guideline is current, which the ICH and EMA documents themselves do not state cleanly.
- Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. read 15 October 2026. View on EUR-LexThe regulation itself. Entered into force 26 May 2018 and applied from 26 May 2021. The Official Journal volume and page could not be opened and are not given. Note that UK legislation sites mark it revoked, which is UK retained-law status and not its status in the EU.
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s regulatory writing team prepares clinical study reports, Investigator’s Brochures, protocols and CTD modules against the current revision of the applicable guideline, and audits document templates and SOPs against guideline changes — the E6(R3) cross-reference move being a current example.